Global biopharma Bristol-Myers Squibb has appointed José Baselga to its board of directors, serving as a member of its science and technology committee.
Dr Baselga is currently the physician in chief at Memorial Sloan Kettering Cancer Center, where he is responsible for the management of patients care, enhancing and expanding programmes in clinical and translational research.
He brings more than 30 years of clinical and research experience to his new position on the board, and his career history has seen him serve as president for the American Association for Cancer Research.
Giovanni Caforia, chairman and chief executive officer of BMS, said: “José is an internationally-recognised physician scientist in oncology with deep experience in teaching at leading academic institutions, pioneering research for targeted cancer therapies and treating patients.
“His close engagement with emerging science across biotech and shared focus on patients brings valuable contributions to helping us advance our strategy and pipeline of transformational medicines.”